Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic (NDM) disorders.
Key Information
NaMuscla is the first licenced antimyotonic proven to:
• control symptoms of myotonia in adult patients with NDM.1,2
• improve patient’s daily lives.1,2
• provide generally well-tolerated, long-term myotonia relief.3
Myotonia is more than an inability to relax muscles.5
Myotonia is a chronic, lifelong condition that impacts NDM patients on a daily basis.5
Untreated myotonia can have dramatic consequences for NDM patients.1
Myotonia restricts everyday life.1
NaMuscla: 1st licensed antimyotonic proven to control symptomatic myotonia.1-2
Proven effective relief from NDM-related myotonia.1
Long-term relief from myotonia irrespective of channelopathy - a retrospective chart review.3
NaMuscla: Well tolerated, and suitable for long-term use.3
Long-term experience in patients with NDM – retropective chart review (4.5y).3
NaMuscla: A daily, long-term treatment for relief from myotonia.1
NaMuscla composition & dosing.1
Each patient should be given a Patient Alert card before initiating treatment with NaMuscla®
Healthcare Professional Education Guide and Patient Alert cards can be requested from: information@lupin.com
References: 1. Summary of Product Characteristics, NaMuscla® 167mg hard capsules, Lupin Europe GmbH 2018. 2. Statland JM, et al. JAMA 2012; 308:(13):1357-65. 3. Suetterlin KJ, et al. JAMA Neurology 2015; 72(12);1531-3. 4. Trivedi JR, et al. Brain 2013; 136:2189-2200. 5. Trip J, et al. J Neurol 2009; 256:939-47. 6. MyoPath (Myotonia Observational Survey of Patient Access to Therapy avoiding Harm) 2018, Lupin, Data on File.
Downloads
Formulary
Pack
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the leaflet. You can also report side effects directly by the Yellow Card Scheme website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Product details
Namuscla (MEXILETINE)
167mg Hard Capsules
| PIP Code |
4097655 |
| Product Licence Number |
PL 35507/0191 |
| Lupin Product Code |
416225 |
| Product Classification |
POM |
| Pack Size |
30 Capsules |
Namuscla Supply Chain
At Lupin Healthcare we recognise the importance of continued supply of branded medicines and are committed to the highest quality standards. With this in mind we supply our products through all three major UK wholesalers.
Contact Us
If you would like to know more about Namuscla, how to order it, available or a detailed stock report please get in touch by email to: information@lupin.com or customer services on 01565 751378
This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit our
Privacy Policy.
LUP-CORP-005s DOP: December 2020
Privacy & Cookies Policy
